Cargando…
Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study
BACKGROUND: The Child–Turcotte–Pugh score (CTP) is the most commonly used tool to assess hepatic reserve and predict survival in hepatocellular cancer (HCC). The CTP stratification accuracy has been questioned and attempts have been made to improve the objectivity of the system. Serum insulin-like g...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502406/ https://www.ncbi.nlm.nih.gov/pubmed/32984091 http://dx.doi.org/10.2147/JHC.S258930 |
_version_ | 1783584219714289664 |
---|---|
author | Lacin, Sahin Yalcin, Suayib Karakas, Yusuf Hassan, Manal M Amin, Hesham Mohamed, Yehia Ibrahim Rashid, Asif Morris, Jeffrey S Xiao, Lianchun Qayyum, Aliya Kaseb, Ahmed O |
author_facet | Lacin, Sahin Yalcin, Suayib Karakas, Yusuf Hassan, Manal M Amin, Hesham Mohamed, Yehia Ibrahim Rashid, Asif Morris, Jeffrey S Xiao, Lianchun Qayyum, Aliya Kaseb, Ahmed O |
author_sort | Lacin, Sahin |
collection | PubMed |
description | BACKGROUND: The Child–Turcotte–Pugh score (CTP) is the most commonly used tool to assess hepatic reserve and predict survival in hepatocellular cancer (HCC). The CTP stratification accuracy has been questioned and attempts have been made to improve the objectivity of the system. Serum insulin-like growth factor-1 (IGF-1)-CTP has been proposed to improve CTP prognostic accuracy. We aimed to validate the IGF-CTP score in our patient population. PATIENTS AND METHODS: A total of 84 diagnosed HCC patients were enrolled prospectively. IGF-CTP scores in addition to CTP scores were calculated. C-index was used to compare the prognostic significance of the two scoring systems and overall survival (OS). RESULTS: Cirrhosis was present in 48 (57.1%) patients, 35 (41.7%) patients were non-cirrhotic, 36 (42.8%) patients were hepatitis B (HBV) positive, and 8 (9.5%) patients were hepatitis C (HCV) positive. Serum IGF-1 levels were significantly lower in cirrhotic compared with non-cirrhotic patients (p=0.04). There was a significant difference in OS rates of patients with serum IGF-1 level <50 ng/mL and patients with serum IGF-1 levels ≥50 ng/mL (p=0.02); the OS rates were 6.5 and 14.8 months, respectively (p=0.02). The median OS of all patients was 7.38 months (95% CI: 5.89–13.79). The estimated C-index for CTP and IGF-CTP scores was 0.605 (95% CI: 0.538, 0.672) and 0.599 (95% CI: 0.543, 0.655), respectively. The U statistics indicated that the C-indices between two scoring systems are not statistically different (P= 0.91). CONCLUSION: This study evaluated IGF-1 levels and the IGF-CTP classification in a predominantly HBV (+) cohort of HCC patients with 41.7% non-cirrhotic. Although the prognostic value was similar, among patients with CTP-A, class those reclassified as IGF-CTP B had shorter OS than those with IGF-CTP score A. Thus, further validations of IGF-CTP score in similar populations may add additional value as a stratification tool to predict HCC outcome. |
format | Online Article Text |
id | pubmed-7502406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75024062020-09-24 Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study Lacin, Sahin Yalcin, Suayib Karakas, Yusuf Hassan, Manal M Amin, Hesham Mohamed, Yehia Ibrahim Rashid, Asif Morris, Jeffrey S Xiao, Lianchun Qayyum, Aliya Kaseb, Ahmed O J Hepatocell Carcinoma Original Research BACKGROUND: The Child–Turcotte–Pugh score (CTP) is the most commonly used tool to assess hepatic reserve and predict survival in hepatocellular cancer (HCC). The CTP stratification accuracy has been questioned and attempts have been made to improve the objectivity of the system. Serum insulin-like growth factor-1 (IGF-1)-CTP has been proposed to improve CTP prognostic accuracy. We aimed to validate the IGF-CTP score in our patient population. PATIENTS AND METHODS: A total of 84 diagnosed HCC patients were enrolled prospectively. IGF-CTP scores in addition to CTP scores were calculated. C-index was used to compare the prognostic significance of the two scoring systems and overall survival (OS). RESULTS: Cirrhosis was present in 48 (57.1%) patients, 35 (41.7%) patients were non-cirrhotic, 36 (42.8%) patients were hepatitis B (HBV) positive, and 8 (9.5%) patients were hepatitis C (HCV) positive. Serum IGF-1 levels were significantly lower in cirrhotic compared with non-cirrhotic patients (p=0.04). There was a significant difference in OS rates of patients with serum IGF-1 level <50 ng/mL and patients with serum IGF-1 levels ≥50 ng/mL (p=0.02); the OS rates were 6.5 and 14.8 months, respectively (p=0.02). The median OS of all patients was 7.38 months (95% CI: 5.89–13.79). The estimated C-index for CTP and IGF-CTP scores was 0.605 (95% CI: 0.538, 0.672) and 0.599 (95% CI: 0.543, 0.655), respectively. The U statistics indicated that the C-indices between two scoring systems are not statistically different (P= 0.91). CONCLUSION: This study evaluated IGF-1 levels and the IGF-CTP classification in a predominantly HBV (+) cohort of HCC patients with 41.7% non-cirrhotic. Although the prognostic value was similar, among patients with CTP-A, class those reclassified as IGF-CTP B had shorter OS than those with IGF-CTP score A. Thus, further validations of IGF-CTP score in similar populations may add additional value as a stratification tool to predict HCC outcome. Dove 2020-09-16 /pmc/articles/PMC7502406/ /pubmed/32984091 http://dx.doi.org/10.2147/JHC.S258930 Text en © 2020 Lacin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lacin, Sahin Yalcin, Suayib Karakas, Yusuf Hassan, Manal M Amin, Hesham Mohamed, Yehia Ibrahim Rashid, Asif Morris, Jeffrey S Xiao, Lianchun Qayyum, Aliya Kaseb, Ahmed O Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study |
title | Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study |
title_full | Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study |
title_fullStr | Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study |
title_full_unstemmed | Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study |
title_short | Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study |
title_sort | prognostic significance of serum insulin-like growth factor-1 in hepatocellular cancer patients: a validation study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502406/ https://www.ncbi.nlm.nih.gov/pubmed/32984091 http://dx.doi.org/10.2147/JHC.S258930 |
work_keys_str_mv | AT lacinsahin prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT yalcinsuayib prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT karakasyusuf prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT hassanmanalm prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT aminhesham prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT mohamedyehiaibrahim prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT rashidasif prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT morrisjeffreys prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT xiaolianchun prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT qayyumaliya prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy AT kasebahmedo prognosticsignificanceofseruminsulinlikegrowthfactor1inhepatocellularcancerpatientsavalidationstudy |